This is a working overview of growth hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-11 and is reviewed periodically as new material appears.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Within the mesh scaffolding of bat wing skin, collagen fibers cross bones perpendicular to the long axes of the bones, therefore mechanical properties of bat wing skin oriented perpendicular to the long axes of the bones exhibit a lower stiffness than the skin that is oriented parallel to the long axes of the bodies. Stiffer skin is necessary for bat wing skin oriented in the direction parallel to the long axes of the bones to prevent too much deformation of bat wing skin during flight (with respect to the bone), resulting in the shearing of the bat wing skin off of the bone. Flexible skin is necessary for the direction perpendicular to the long axes of the bones for facilitating the shape changes needed for movement and control during flight. This anisotropy of bat wing skin is also useful as method of storing and releasing elastic energy, particularly during the downstroke. During the downstroke, the bat extends its wing and the wing skin experiences an aerodynamic force. The wing skin expands and counteracts the aerodynamic force. After the wing is fully extended, the orientation of the wing is nearly vertical and the aerodynamic forces on the wing are reduced. As the aerodynamic force is reduced, the wing recoils, drawing the digits of the wings together in preparation for the upstroke.
=== Methionine salvage === Homocysteine can be recycled into methionine. This process uses N5-methyl tetrahydrofolate as the methyl donor and Methylcobalamin (vitamin B12)-related enzymes. More detail on these enzymes can be found in the article for methionine synthase.
===== Pakistan ===== During the Cold War and the War in Afghanistan, the US relied on Pakistan to intervene in Afghanistan, and the US military aid to Pakistan at this time caused India's dissatisfaction. In 2009, Robert Blake, Assistant Secretary of State for South and Central Asian Affairs, dismissed any concerns over a rift with India regarding American Af-Pak policy. Calling India and the United States "natural allies", Blake said that the United States cannot afford to meet the strategic priorities in Pakistan and Afghanistan at "the expense of India". From the mid-2000s to 2025, India halved its arms imports from Russia, and has pivoted to buying more from the United States and France. At the same time, Pakistan has doubled its arm imports from China, resulting in a realignment of ties.
He also met with King Philippe of Belgium and Belgian prime minister Alexander de Croo as well as with former Swedish prime minister Stefan Löfven, Danish prime minister Mette Frederiksen and other leaders. In September 2023, Finance Minister Fernando Haddad said Lula was pushing for the EU-Mercosur trade deal to be concluded in 2023. In November 2023, Lula told EU's Commission chief Ursula Von der Leyen that he wished to finish the deal by the end of 2023 when Brazil still presided Mercorsur's rotating presidency.
=== Discontinued === ABT-436 – vasopressin V1b receptor antagonist – alcoholism Adrogolide (ABT-431; DAS-431) – dopamine D1 receptor agonist – cocaine-related disorders ADX-629 – aldehyde inhibitor / reactive aldehyde species (RASP) inhibitor – alcoholism, alcoholic hepatitis ADX-10061 (CEE-310; CEE-03-310; NNC-010687; NNC-687) – dopamine D1 receptor antagonist – smoking withdrawal, substance-related disorders ADX-71441 – GABAB receptor positive allosteric modulator – alcoholism, cocaine-related disorders, substance-related disorders Anatabine (RCP-006) – nicotinic acetylcholine receptor agonist – smoking withdrawal ANS-6637 (GS-6637; GS-6673) – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism, opioid-related disorders, smoking withdrawal, substance-related disorders Arbaclofen placarbil (R-baclofen placarbil; XP-19986) – GABAB receptor agonist – alcoholism ASP-8062 – GABAB receptor modulator – opioid-related disorders Aticaprant (AVTX-501; CERC-501; JNJ-3964; JNJ-67953964; JNJ-67953964-AAA; LY-2456302) – κ-opioid receptor antagonist – alcoholism, cocaine-related disorders, smoking withdrawal Azasetron (nazasetron; Serotone; Y-25130) – serotonin 5-HT3 receptor antagonist – cocaine-related disorders AZD-4041 – orexin OX1 receptor antagonist – smoking withdrawal Baclofen/samidorphan (ALKS-29; ALKS-33/baclofen; baclofen/ALKS-33) – combination of baclofen (GABAB receptor agonist) and samidorphan (μ-opioid receptor antagonist) – alcoholism Befloxatone (MD-370503) – monoamine oxidase A (MAO-A) inhibitor – smoking withdrawal BP-897 – dopamine D3 receptor agonist – cocaine-related disorders BR-9003 (BR-9003A) – undefined mechanism of action – smoking withdrawal BTRX-246040 (LY-2940094) – nociceptin receptor agonist – alcoholism Buprenorphine/naloxone (NanoBUP; NTC-0510; NTC-510) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Buprenorphine/samidorphan (ALKS 33-BUP; ALKS 33/buprenorphine; ALKS-5461; BUP-ALKS 33; buprenorphine/ALKS-33; buprenorphine/RDC 0313; RDC 0313/buprenorphine; samidorphan/buprenorphine) – combination of buprenorphine (non-selective opioid receptor modulator) and samidorphan (μ-opioid receptor antagonist) – cocaine-related disorders Cannabidiol (CBD; synthetic cannabidiol; RAD-011) – cannabinoid/various actions – substance-related disorders CVL-936 – dopamine D2 and D3 receptor antagonist – substance-related disorders CX-1739 – AMPA receptor positive allosteric modulator (ampakine) – substance-related disorders Deudimethyltryptamine (HLP004; HLP-004; CYB004; CYB-004; DMT-d10; deuterated dimethyltryptamine; dDMT) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – substance-related disorders Deupsilocin (HLP003; HLP-003; CYB003; CYB-003; psilocin-d10; deuterated psilocin) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism Dianicline (SSR-591813) – nicotinic acetylcholine receptor agonist – smoking withdrawal Drinabant (AVE-1625; INDV-5004; OPNT-004) – cannabinoid CB1 receptor antagonist – substance-related disorders Ecopipam (EBS-101; PSYRX-101; SCH-39166) – dopamine D1 receptor antagonist – cocaine-related disorders Eglumetad (eglumegad; LY-354740) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist – smoking withdrawal Elinzanetant (BAY-3427080; GSK-1144814A; GSK-1144814; Lynkuet; NT-814) – neurokinin NK1 and NK3 receptor antagonist – opioid-related disorders Femoxetine (femoxitine; FG-4963; Malexil; NNC-204963) – selective serotonin reuptake inhibitor (SSRI) – alcoholism Gabapentin enacarbil (ASP8825; Gabapentin-XP; GSK-1838262; Horizant; Regnite; Solzira; XP13512) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel blocker) – alcoholism Gepirone (Ariza; BMY-13805; Exxua; MJ-13805; Org-33062; TGFK07AD; Travivo; Variza) – serotonin 5-HT1A receptor agonist – cocaine-related disorders Istradefylline (KW-6002; Nourianz; Nouriast) – adenosine A2 receptor antagonist ITI-333 – serotonin 5-HT2A receptor antagonist, dopamine D1 receptor antagonist, α1A-adrenergic receptor antagonist, μ-opioid receptor partial agonist – substance-related disorders JNJ-39393406 – α7 subunit-containing nicotinic acetylcholine receptor positive allosteric modulator – smoking withdrawal JZP-150 – fatty acid amide hydrolase (FAAH) inhibitor – alcoholism Lisdexamfetamine (LDX; Elvanse; NRP-104; S-877489; SHP-489; SPD-489; Tyvense; Venvanse; Vyvanse) – norepinephrine–dopamine releasing agent (NDRA) – cocaine-related disorders Lorcaserin (APD-356; Belviq; E2023; Venespri) – serotonin 5-HT2C receptor agonist – smoking withdrawal Manifaxine (BW-1555U88; GW-320659) – norepinephrine–dopamine reuptake inhibitor (NDRI) – smoking withdrawal Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – smoking withdrawal Nalmefene (CPH-101; JF-1; Lu AA36143; Nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – smoking withdrawal Nepicastat oral (APL-1401; SYN-117) – dopamine β-hydroxylase (DBH) inhibitor – cocaine-related disorders Neramexane (KRP-209; MRZ-2/579) – NMDA receptor antagonist, nicotinic acetylcholine receptor antagonist – alcoholism NIC-002 (NIC002; CYT002-NicQβ; Nicotine-Qβ) – immunostimulant (nicotine vaccine) – smoking withdrawal NicVAX – immunostimulant (nicotine vaccine) – smoking withdrawal Nornicotine – nicotinic acetylcholine receptor agonist – smoking withdrawal NS-2359 (GSK-372475) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – alcoholism NYX-783 – ionotropic glutamate NMDA receptor modulator – alcoholism, opioid-related disorders OREX-1019 – μ-opioid receptor agonist, δ-opioid receptor antagonist, κ-opioid receptor antagonist, nociceptin receptor agonist – cocaine-related disorders OREX-1038 – μ-opioid receptor agonist – cocaine-related disorders, opioid-related disorders Oxytocin intranasal (Syntocinon Nasal Spray; TUR-001) – oxytocin receptor agonist – alcoholism Quetiapine (FK-949; FK949E; ICI-204636; Seroquel) – atypical antipsychotic (non-selective monoamine receptor modulator) – alcoholism Rimonabant (Acomplia; SR-141716; SR-141716A; Zimulti) – cannabinoid CB1 receptor antagonist – smoking withdrawal Risperidone (JNJ-410397-AAA; R-64766; R064766; Risperdal; Risperdal Consta; Risperdal Depot) – atypical antipsychotic (non-selective monoamine receptor modulator) – substance-related disorders RTI-113 – dopamine reuptake inhibitor (DRI) (cocaine analogue) – cocaine-related disorders Samidorphan (ALKS-33; RDC-0313; RDC-0313-00) – μ-opioid receptor antagonist – alcoholism, substance-related disorders Sembragiline (EVT-302; RG-1577; RO-4602522) – monoamine oxidase B (MAO-B) inhibitor – smoking withdrawal Serlopitant (JTS-661; MK-0594; VPD-737) – neurokinin NK1 receptor antagonist – alcoholism Surinabant (SR-147778; SR147778) – cannabinoid CB1 receptor antagonist – alcoholism, smoking withdrawal TA-NIC – immunostimulant (nicotine vaccine) – smoking withdrawal Tradipitant (LY-686017; Nereus; VLY-686) – neurokinin NK1 receptor antagonist – alcoholism Verucerfont (GSK-561679; NBI-77860) – corticotropin-releasing factor 1 (CRF1) receptor antagonist Vigabatrin (γ-vinyl-GABA; gamma-vinyl-GABA; GVG; M071754; MDL-71754; RMI-71754; Sabril; Sabrilex) – GABA transaminase (GABA-T) inhibitor – cocaine-related disorders, substance-related disorders
Sources: en.wikipedia.org
=== Healthcare === Kiggans voted against extending Affordable Care Act subsidies in December 2025. Kiggans supports banning abortions after fifteen weeks of pregnancy, except for in cases of rape, incest, or to protect the life of the mother. In June 2022, she expressed support for the U.S. Supreme Court's ruling in Dobbs v. Jackson Women's Health Organization, which overruled Roe v. Wade.
She served as the de facto head of government until she was deposed in the 2021 coup d'état by Commander-in-Chief of Defence Services Min Aung Hlaing, who created the extraconstitutional posts of chairman of the State Administration Council and prime minister for himself to lead the government. The president is elected by members of parliament, not by the general population; specifically the Presidential Electoral College, a three-committee body composed of members of parliament, elects the president. Each of the three committees, made up of Amyotha Hluttaw, Pyithu Hluttaw members of parliament, or military-appointed lawmakers, nominates a candidate for presidency. The presidency is the most powerful position in the civilian leadership structure. Even when an elected civilian government is in place, the president has no command authority over the Tatmadaw, and his executive authority is counterbalanced by the significant governance powers of Commander-in-Chief of Defence Services. The current president is Min Aung Hlaing, who assumed office 10 April 2026, having previously exercised the duties of the role from 2024 to 2026.
=== Physical methods === Heat treatment − Treating food with heat, such as blanching or roasting, de-naturates enzymes and destroys the reactants responsible for browning. Blanching is used, for example, in winemaking, tea processing, storing nuts and bacon, and preparing vegetables for freezing preservation. Meat is often partially browned under high heat before being incorporated into a larger preparation to be cooked at a lower temperature which produces less browning. Cold treatment − Refrigeration and freezing are the most common ways of storing food, preventing decay. The activity of browning enzymes, i.e., rate of reaction, drops in low temperatures. Thus, refrigeration helps to keep the initial look, color, and flavour of fresh vegetables and fruits. Refrigeration is also used during distribution and retailing of fruits and vegetables. Oxygen elimination − Presence of oxygen is crucial for enzymatic browning, therefore eliminating oxygen from the environment helps to slow down the browning reaction. Withdrawing air or replacing it with other gases (e.g., N2 or CO2) during preservation, such as in vacuum-packaging or modified atmosphere packaging, wine or juice bottling, using impermeable films or edible coatings, dipping into salt or sugar solutions, keeps the food away from direct contact with oxygen. Impermeable films made of plastic or other materials prevent food being exposed to oxygen in the air and avoid moisture loss.
Most of the world's cocaine is produced in South America, particularly in the Andean region. The environmental destruction caused by the production of cocaine has been well documented, with reports made the UN and other government bodies. Due to the illegal nature of coca production, farmers make little effort in soil conservation and sustainability practices as seen in the high mobility and short life of coca plots in Colombia. One of the major implications of cocaine production is deforestation as large areas of forest are cleared for coca cultivation. The UNODC approximated that 97,622 hectares of primary forest were cleared for coca cultivation during 2001–2004 in the Andean region. This further causes habitat destruction, especially in biodiversity hotspots, areas rich in a variety of species. Such areas are chosen for coca cultivation due to their remote locations, minimising chances of detection. Deforestation impacts soil erosion which further inhibits the survival of native species. The use of pesticides can also severely affect the environment. Farmers are able to use unregulated and highly toxic pesticides due to the clandestine nature of drug production. The use of such pesticides can have both direct and indirect effects on the ecosystem. Where lethal levels of exposure directly cause the death of fauna, which is further carried up the food chain where secondary feeders who consume the poisoned animals are also impacted.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.